HSD3B1 and overall survival (OS) in men with low-volume (LV) metastatic prostate cancer (PCa) treated with androgen deprivation therapy (ADT) or chemohormonal therapy in the CHAARTED Randomized trial.
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: University of Michigan, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Cleveland Clinic, University of Wisconsin–Madison, UW Health University Hospital, Harvard University, Dana-Farber/Harvard Cancer Center, University of Virginia, Sidney Kimmel Comprehensive Cancer Center, University of Kentucky
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2946852833